BSD Medical Corporation (NASDAQ: BSDM) (the "Company" or "BSD") announced that a study titled "BSD2000 Deep Hyperthermia Combined with Chemotherapy of PT regimen in Patients with Non-small Cell Lung Cancer" has been published in the current issue of The Chinese Journal of Lung Cancer (February 2010;13(2):132-135) by Yang, Zhao, and Wang. The article can be accessed here (free online registration required). The clinical study, conducted at a prestigious hospital in China, involved 60 patients with non-small cell lung cancer (NSCLC) who were randomized to receive either chemotherapy (cisplatin and paclitaxel) combined with hyperthermia (delivered using the BSD-2000 Hyperthermia System) or chemotherapy without hyperthermia.

The researchers compared the short-term tumor regression rate, side effects and quality of life improvement between the two groups. Efficacy was based on World Health Organization standards and included those patients who had a complete response (CR=100% tumor disappearance) or a partial response (PR=50% to